Abstract
Strained ruthenium (Ru) complexes have been synthesized and characterized as novel agents for photodynamic therapy (PDT). The complexes are inert until triggered by visible light, which induces ligand loss and covalent modification of DNA. An increase in cytotoxicity of 2 orders of magnitude is observed with light activation in cancer cells, and the compounds display potencies superior to cisplatin against 3D tumor spheroids. The use of intramolecular strain may be applied as a general paradigm to develop light-activated ruthenium complexes for PDT applications.
Keywords
MeSH Terms
Affiliated Institutions
Related Publications
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433
Transition metal complexes are of increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru(II) ...
Principles and pitfalls in designing site‐directed peptide ligands
Abstract An immunoglobulin light chain dimer with a large generic binding cavity was used as a host molecule for designing a series of peptide guest ligands. In a screening proc...
Photoredox Catalysis with Visible Light
On the sunny side: Recent examples of visible-light-promoted photoredox catalysis in the presence of [Ru(bpy)3]2+ as an efficient photocatalyst have set new standards for conduc...
Publication Info
- Year
- 2012
- Type
- article
- Volume
- 134
- Issue
- 20
- Pages
- 8324-8327
- Citations
- 485
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1021/ja3009677
- PMID
- 22553960